Response to article by Johnna Perdrizet et al.,"Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants".
Jorge A Gómez, Thatiana de Jesus Pereira Pinto, Javier Nieto Guevara, Tatiana Guimarães de Noronha
Author Information
- Jorge A Gómez: Vaccine Department, GlaxoSmithKline, Buenos Aires, Argentina. ORCID
- Thatiana de Jesus Pereira Pinto: Vaccine Department, GlaxoSmithKline, Rio de Janeiro, Brazil.
- Javier Nieto Guevara: Vaccine Department, GlaxoSmithKline, Panama City, Panama.
- Tatiana Guimarães de Noronha: Institute of Technology for Immunobiologicals of Bio-Manguinhos, FIOCRUZ, Rio de Janeiro, Brazil.
No abstract text available.
- Hum Vaccin Immunother. 2021 Apr 3;17(4):1162-1172
[PMID: 32966176]
- PLoS One. 2016 Dec 12;11(12):e0166736
[PMID: 27941979]
- Lancet Respir Med. 2014 Jun;2(6):464-71
[PMID: 24726406]
- Pediatr Infect Dis J. 2019 Oct;38(10):e260-e265
[PMID: 31568144]
- Med Decis Making. 2012 Sep-Oct;32(5):667-77
[PMID: 22990082]
- Vaccine. 2009 Jul 23;27(34):4694-703
[PMID: 19520197]
- Epidemiol Infect. 2019 Jan;147:e93
[PMID: 30869012]
- Vaccine. 2015 May 28;33(23):2684-9
[PMID: 25887086]
- PLoS One. 2015 Mar 17;10(3):e0120290
[PMID: 25781031]
- Hum Vaccin Immunother. 2021 Apr 3;17(4):1173-1180
[PMID: 32966144]
- PLoS One. 2017 Jun 8;12(6):e0179222
[PMID: 28594913]
Brazil
Cost-Benefit Analysis
Humans
Infant
Pneumococcal Vaccines
Vaccines, Conjugate
10-valent pneumococcal conjugate vaccine
Pneumococcal Vaccines
Vaccines, Conjugate
